Overview

  • Product name
  • Description
    Rabbit polyclonal to FCP1
  • Tested applications
    Suitable for: WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat, Xenopus laevis, Zebrafish
  • Immunogen

    Recombinant fragment, corresponding to a region within amino acids 131-279 of Human FCP1 (Q9Y5B0).

  • Positive control
    • A549, HeLa, HepG2 and HCT116 whole cell lysates.

Properties

Applications

Our Abpromise guarantee covers the use of ab126107 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/3000. Predicted molecular weight: 104 kDa.

Target

  • Function
    Processively dephosphorylates 'Ser-2' and 'Ser-5' of the heptad repeats YSPTSPS in the C-terminal domain of the largest RNA polymerase II subunit. This promotes the activity of RNA polymerase II.
  • Tissue specificity
    Ubiquitously expressed. Isoform 3 is expressed in heart, brain, placenta, lung, liver, skeletal muscle, kidney and placenta.
  • Involvement in disease
    Defects in CTDP1 are a cause of congenital cataracts facial dysmorphism and neuropathy syndrome (CCFDN) [MIM:604168]. CCFDN is an autosomal recessive developmental disorder that occurs in an endogamous group of Vlax Roma (Gypsies). The syndrome is characterized by a complex clinical phenotype with seemingly unrelated features involving multiple organs and systems. Developmental abnormalities include congenital cataracts and microcorneae, hypomyelination of the peripheral nervous system, impaired physical growth, delayed early motor and intellectual development, facial dysmorphism and hypogonadism. Central nervous system involvement, with cerebral and spinal cord atrophy, may be the result of disrupted development with superimposed degenerative changes. Affected individuals are prone to severe rhabdomyolysis after viral infections and to serious complications related to general anesthesia (such as pulmonary edema and epileptic seizures).
  • Sequence similarities
    Contains 1 BRCT domain.
    Contains 1 FCP1 homology domain.
  • Post-translational
    modifications
    Phosphorylated. In the presence of TFIIF, the phosphorylated form has an increased CTD phosphatase activity. The phosphorylation is required for the physical interaction with GTF2F1.
  • Cellular localization
    Nucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • CCFDN antibody
    • CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) phosphatase, subunit 1 antibody
    • CTD of POLR2A, phosphatase of, subunit 1 antibody
    • CTDP1 antibody
    • CTDP1_HUMAN antibody
    • EC 3.1.3.16 antibody
    • RNA polymerase II subunit A C terminal domain phosphatase antibody
    • RNA polymerase II subunit A C-terminal domain phosphatase antibody
    • Serine phosphatase FCP1a antibody
    • TFIIF associating CTD phosphatase antibody
    • TFIIF-associating CTD phosphatase 1 antibody
    • TFIIF-associating CTD phosphatase antibody
    • Transcription factor IIF-associating CTD phosphatase 1 antibody
    see all

Images

  • Anti-FCP1 antibody (ab126107) at 1/1000 dilution + A549 cell lysate at 30 µg

    Predicted band size : 104 kDa

References

ab126107 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab126107.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up